

# The Impact of Achondroplasia on Quality of Life, Healthcare Resource Use, Clinical, Socio-economic and Psychosocial state of the Individual (LIAISE)

**First published:** 23/01/2017

**Last updated:** 14/01/2021

Study

Finalised

## Administrative details

### EU PAS number

EUPAS17347

---

### Study ID

39022

---

### DARWIN EU® study

No

---

### Study countries

- Austria
- Denmark
- Germany

- Italy
  - Spain
  - Sweden
- 

### Study description

Observational study looking at the burden of illness in achondroplasia patients aged 5-70. The study will include a 5 year review of historical clinical data as well as a single point collection of questionnaire data to look at the impact on the following in individuals with achondroplasia versus a normative population: - Quality of life - Clinical burden - Healthcare resource use - Socio-economic burden - Psychosocial burden Up to 300 subjects will be included in 13 sites in Germany, Austria, Spain, Italy, Denmark and Sweden

---

### Study status

Finalised

## Research institutions and networks

### Institutions

#### BioMarin Pharmaceuticals

**First published:** 01/02/2024

**Last updated:** 01/02/2024

**Institution**

Multiple centres: 13 centres are involved in the study

## Contact details

### Study institution contact

Director Program [medinfoeu@bmrn.com](mailto:medinfoeu@bmrn.com)

Study contact

[medinfoeu@bmrn.com](mailto:medinfoeu@bmrn.com)

### Primary lead investigator

Director Program

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned: 03/11/2016

Actual: 03/11/2016

---

### Study start date

Planned: 30/10/2017

Actual: 22/12/2017

---

### Data analysis start date

Planned: 28/04/2018

Actual: 31/08/2018

---

### **Date of interim report, if expected**

Planned: 29/06/2018

Actual: 19/10/2018

---

### **Date of final study report**

Planned: 14/08/2020

Actual: 19/11/2020

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

BioMarin Pharmaceutical Inc

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

**Study topic:**

Disease /health condition

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Disease epidemiology

**Data collection methods:**

Combined primary data collection and secondary use of data

---

**Main study objective:**

The objectives of the study are to describe the impact on the following in individuals with achondroplasia versus a normative population in Denmark, Germany, Spain and Sweden: • Quality of life • Clinical burden • Healthcare resource use • Socio-economic burden • Psychosocial burden

## Study Design

**Non-interventional study design**

Cross-sectional

Other

---

**Non-interventional study design, other**

Retrospective

## Study drug and medical condition

## **Medical condition to be studied**

Dwarfism

## Population studied

### **Short description of the study population**

Achondroplasia patients aged 5-70 years.

---

### **Age groups**

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

---

### **Special population of interest**

Other

---

### **Special population of interest, other**

Achondroplasia patients

---

### **Estimated number of subjects**

300

## Study design details

## Outcomes

1. Patient Reported Outcomes (PRO) and Activities of Daily Living (ADL)
  2. Clinical burden for at least the last five years
  3. Healthcare resource use for at least the last five years
  4. Socio-economic burden
  5. Psychosocial burden
- 

## Data analysis plan

Statistical analysis will be carried out using SAS software. An interim analysis will be performed after nine months of enrolment. Continuous variables will be described (distribution) by their mean, standard deviation, median, quartiles one and three, extreme values (minimum and maximum) and the number of missing data and will be compared to normative data. Categorical variables will be described (counts) by the absolute and relative (%) frequency of each class, and the number of missing data and will be compared to normative data.

## Data management

### Data sources

#### Data sources (types)

Other

---

#### Data sources (types), other

Prospective patient-based data collection, Historical data from clinical records

### Use of a Common Data Model (CDM)

#### CDM mapping

No

### Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No